Derived from the Smithburn vaccine strain (origin = Uganda)

Attenuated by successive IC^a passage in newborn mice and in embryonated eggs (resulting in a neurotropic strain); produced in cell culture since 1971

Derived from South African field strain

Inactivation with formaldehyde

Contains adjuvant

Needs only one injection

Long duration of protective immunity (entire economic life of animals)

Inexpensive production costs

No adverse effects

No contraindications

May induce abortions and fœtal malformations → major contraindications for use in pregnant animals

Transient viraemia

Possible residual human pathogenicity

Possible reassortment with field wild–type virus strains

Need two injections during the first year and booster doses annually

Short duration of protective immunity (necessitating annual booster doses)

Expensive production costs

Prefer live vaccine in countries/regions where the RVF is enzootic

Vaccinate before the reproductive season

Prefer inactivated vaccine in countries/regions newly infected or free but with a high risk of RVFV introduction

Do not allow the differentiation of vaccinated and naturally-infected animals (i.e., no « DIVA^b test » available)

Age of vaccination: > 6 month of age